Technology

Pioneering Targeted Cancer Treatments

Radioactive Biopolymer Technology Platform

At Blue Wave Therapeutics, we are at the forefront of developing a targeted radioactive biopolymer technology platform. This innovative platform uses targeted biopolymer nanoparticles to deliver radionuclides directly to tumor cells, providing highly targeted cancer treatments that minimize damage to healthy tissues and enhance therapeutic efficacy. Our approach represents a significant advancement in the field of nuclear medicine and oncology.

Pipeline

Advancing Innovative Therapies

Blue Wave Therapeutics is committed to the development of groundbreaking therapies for the treatment of solid tumors. Our pipeline reflects our rigorous scientific approach and dedication to bringing new therapeutic solutions to patients with critical unmet needs. Besides our first product candidate ARAspheres, Blue Wave is exploring two further candidates with undisclosed target and indication.:

Current Phase

Preclinical Development

ARAspheres (225Ac-RGD-Alginate Nanospheres) are integrin-targeting alginate nanoparticles loaded with Actinium-225, designed to deliver targeted alpha radiation to glioblastoma cells. This innovative approach aims to improve patient outcomes by precisely targeting tumor cells and minimizing damage to healthy tissue.

Future Applications

Expanding the Platform

Beyond glioblastoma, our radioactive biopolymer platform has the potential to treat other solid tumors with limited therapeutic options. We are exploring applications for cancers with brain metastases, as well as liver, prostate, thyroid, pancreatic, and breast cancers.

Glioblastoma

Targeting Aggressive Brain Tumors

Glioblastoma is one of the most aggressive and difficult-to-treat brain tumors. Blue Wave Therapeutics is developing ARAspheres to address this critical unmet medical need. Our technology targets glioblastoma cells with precision, delivering alpha radiation directly to the tumor and sparing healthy brain tissue. Our goal is to significantly improve survival rates and quality of life for patients with glioblastoma.

ARAspheres

Innovative Nanoparticle Therapy

ARAspheres represent the first product candidate from Blue Wave Therapeutics’ targeted biopolymer platform: they are designed to specifically carry radionuclides to tumor cells. In fact, these nanoparticles use a targeting peptide, RGD, to bind specifically to tumor cell receptors, ensuring precise delivery of alpha radiation. This innovative approach holds great promise for treating various solid tumors, starting with glioblastoma.

Administration Modality

Patient with glioblastoma

The tumor is removed by surgery

After surgery

After surgery, ARAspheres are injected into the surgical cavity and diffuse into the brain

Residual tumor cells

Residual tumor cells are irradiated continuously, until radionuclide decays

Cavity Tissue Infusion

Upon biopolymer degradation, the brain tissue slowly fills the cavity

Key R&D Milestones

Q4 2024

Production of RGD-alginate nanoparticles

Q2 2025

Optimization of ARAspheres for radionuclide labelling

Acceptable toxicity in rat C6 GBM model

Preclinical proof of principle in rat C6 GBM model

Q3 2025

Establish in vitro 3D model of glioblastoma

Q1 2026

Manufacturing ready for tech transfer to CMO

Q1 2027

Confirm preclinical proof of concept

Publications

Sharing Our Scientific Discoveries

At Blue Wave Therapeutics, we believe in the importance of scientific transparency and collaboration. Our publications section will feature research papers, articles, and other relevant publications.

Michele December 20, 2020July 11, 2024